دورية أكاديمية
أعرض في EDS

Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis.

التفاصيل البيبلوغرافية
العنوان: Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis.
المؤلفون: Osses DF; Department of Radiology & Nuclear Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. d.osses@erasmusmc.nl.; Department of Urology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. d.osses@erasmusmc.nl., Roobol MJ; Department of Urology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. m.roobol@erasmusmc.nl., Schoots IG; Department of Radiology & Nuclear Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. i.schoots@erasmusmc.nl.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2019 Apr 02; Vol. 20 (7). Date of Electronic Publication: 2019 Apr 02.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Magnetic Resonance Imaging*, Biomarkers, Tumor/*metabolism , Prostatic Neoplasms/*diagnosis , Prostatic Neoplasms/*diagnostic imaging, Humans ; Male ; Risk Factors
مستخلص: This review discusses the most recent evidence for currently available risk stratification tools in the detection of clinically significant prostate cancer (csPCa), and evaluates diagnostic strategies that combine these tools. Novel blood biomarkers, such as the Prostate Health Index (PHI) and 4Kscore, show similar ability to predict csPCa. Prostate cancer antigen 3 (PCA3) is a urinary biomarker that has inferior prediction of csPCa compared to PHI, but may be combined with other markers like TMPRSS2-ERG to improve its performance. Original risk calculators (RCs) have the advantage of incorporating easy to retrieve clinical variables and being freely accessible as a web tool/mobile application. RCs perform similarly well as most novel biomarkers. New promising risk models including novel (genetic) markers are the SelectMDx and Stockholm-3 model (S3M). Prostate magnetic resonance imaging (MRI) has evolved as an appealing tool in the diagnostic arsenal with even stratifying abilities, including in the initial biopsy setting. Merging biomarkers, RCs and MRI results in higher performances than their use as standalone tests. In the current era of prostate MRI, the way forward seems to be multivariable risk assessment based on blood and clinical parameters, potentially extended with information from urine samples, as a triaging test for the selection of candidates for MRI and biopsy.
References: Lancet Oncol. 2019 Jan;20(1):100-109. (PMID: 30470502)
J Natl Compr Canc Netw. 2016 May;14(5):509-19. (PMID: 27160230)
Eur Urol. 2015 Sep;68(3):464-70. (PMID: 25454615)
Sci Rep. 2016 Oct 17;6:35364. (PMID: 27748407)
Clin Chem. 2002 Aug;48(8):1279-87. (PMID: 12142385)
Prostate. 2010 Jan 1;70(1):10-6. (PMID: 19708043)
Eur Urol. 2016 Jan;69(1):16-40. (PMID: 26427566)
Eur Urol. 2018 Jan;73(1):31-32. (PMID: 28965689)
Eur Urol. 2017 Aug;72(2):282-288. (PMID: 27574821)
Urol Oncol. 2019 Feb;37(2):138-144. (PMID: 30528698)
J Urol. 2015 Jul;194(1):65-72. (PMID: 25636659)
Eur Urol. 2014 Mar;65(3):534-42. (PMID: 23201468)
CA Cancer J Clin. 2018 Sep;68(5):329-339. (PMID: 30191964)
Cancer Res. 1999 Dec 1;59(23):5975-9. (PMID: 10606244)
Eur Urol. 2019 Apr;75(4):570-578. (PMID: 30477981)
Eur Urol. 2010 Jan;57(1):79-85. (PMID: 19733959)
Eur Urol. 2019 Feb;75(2):310-318. (PMID: 30082150)
BMJ Evid Based Med. 2019 Jun;24(3):116-117. (PMID: 30355658)
J Exp Clin Cancer Res. 2015 Feb 06;34:15. (PMID: 25651917)
Int J Mol Sci. 2013 Aug 29;14(9):17767-80. (PMID: 23994838)
Eur Urol. 2014 Dec;66(6):1109-15. (PMID: 25168616)
Clin Cancer Res. 2015 Jul 1;21(13):3061-70. (PMID: 25788493)
Sci Transl Med. 2011 Aug 3;3(94):94ra72. (PMID: 21813756)
Ann Transl Med. 2016 May;4(10):205. (PMID: 27294246)
BJU Int. 2017 Dec;120(6):774-781. (PMID: 28207981)
J Urol. 2018 Dec;200(6):1227-1234. (PMID: 30017964)
BJU Int. 2017 Dec;120(6):793-798. (PMID: 28058757)
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):57-63. (PMID: 29259293)
Curr Opin Urol. 2016 Sep;26(5):459-65. (PMID: 27262138)
Lancet Oncol. 2015 Dec;16(16):1667-76. (PMID: 26563502)
Lancet. 2014 Dec 6;384(9959):2027-35. (PMID: 25108889)
J Clin Oncol. 2014 Dec 20;32(36):4066-72. (PMID: 25385735)
Ann Oncol. 2015 May;26(5):848-864. (PMID: 25403590)
Lancet. 2017 Feb 25;389(10071):815-822. (PMID: 28110982)
Prostate. 2015 Dec;75(16):1868-76. (PMID: 26310814)
Eur Urol. 2008 Nov;54(5):1081-8. (PMID: 18602209)
Urology. 2014 Jun;83(6):1362-7. (PMID: 24862395)
BJU Int. 2017 Nov;120(5):659-665. (PMID: 28370948)
Ann Intern Med. 2017 Oct 03;167(7):449-455. (PMID: 28869989)
Cochrane Database Syst Rev. 2019 Apr 25;4:CD012663. (PMID: 31022301)
Eur Urol. 2018 Dec;74(6):722-728. (PMID: 30001824)
Int J Cancer. 2004 Aug 20;111(2):310-5. (PMID: 15197788)
Curr Opin Urol. 2017 May;27(3):210-216. (PMID: 28212119)
Urology. 2017 Apr;102:183-189. (PMID: 27919668)
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):137-142. (PMID: 30171228)
Eur Urol. 2017 Aug;72(2):250-266. (PMID: 28336078)
Eur Urol. 2019 Mar;75(3):374-377. (PMID: 30420254)
Prostate. 2015 Jan;75(1):103-11. (PMID: 25327361)
Eur Urol. 2017 Dec;72(6):888-896. (PMID: 28400169)
Urol Oncol. 2018 Jul;36(7):341.e1-341.e7. (PMID: 29753548)
Eur Urol. 2015 Oct;68(4):713-20. (PMID: 26116294)
Eur Urol. 2013 Feb;63(2):201-9. (PMID: 22854248)
World J Urol. 2012 Apr;30(2):149-55. (PMID: 22203238)
Rev Urol. 2017;19(3):149-155. (PMID: 29302237)
Eur Urol Focus. 2019 Sep;5(5):815-822. (PMID: 29802053)
JAMA Oncol. 2018 May 1;4(5):678-685. (PMID: 29470570)
Eur Urol. 2019 Apr;75(4):558-561. (PMID: 30396635)
Exp Cell Res. 2018 Feb 1;363(1):26-32. (PMID: 29317218)
PLoS One. 2018 Aug 9;13(8):e0201384. (PMID: 30092002)
Urology. 2017 Jan;99:174-179. (PMID: 27562202)
Eur Urol Focus. 2015 Sep;1(2):185-190. (PMID: 28723432)
Health Technol Assess. 2018 Jul;22(39):1-176. (PMID: 30040065)
BJU Int. 2017 Jul;120(1):61-68. (PMID: 27743489)
Eur Urol Focus. 2019 Jan;5(1):54-61. (PMID: 29422418)
Eur Urol. 2016 Jul;70(1):45-53. (PMID: 25985884)
Eur Urol. 2017 Jul;72(1):45-51. (PMID: 28162815)
BJU Int. 2018 Apr;121(4):619-626. (PMID: 29232037)
J Urol. 2014 Jun;191(6):1743-8. (PMID: 24333241)
Eur Urol. 2018 Aug;74(2):204-210. (PMID: 29331214)
Urology. 2002 Jun;59(6):797-802. (PMID: 12031356)
J Urol. 2018 Dec;200(6):1215-1220. (PMID: 29906434)
Eur Urol. 2019 Apr;75(4):582-590. (PMID: 30522912)
BJU Int. 2016 Jan;117(1):72-9. (PMID: 25818705)
Curr Med Chem. 2019;26(6):1045-1058. (PMID: 30215331)
Eur Urol. 2009 Oct;56(4):659-67. (PMID: 19304372)
J Urol. 2016 Dec;196(6):1613-1618. (PMID: 27320841)
BJU Int. 2016 Nov;118(5):706-713. (PMID: 26833820)
J Natl Cancer Inst. 2014 Dec 13;107(1):366. (PMID: 25505238)
Rev Urol. 2015;17(4):231-40. (PMID: 26839521)
N Engl J Med. 2018 May 10;378(19):1767-1777. (PMID: 29552975)
J Urol. 2013 Jul;190(1):64-9. (PMID: 23416644)
Urology. 2007 Mar;69(3):532-5. (PMID: 17382159)
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):101-109. (PMID: 30127462)
Eur Urol. 2015 Jul;68(1):8-19. (PMID: 25454618)
Eur Urol. 2016 Nov;70(5):740-748. (PMID: 27108162)
Eur Urol. 2015 Jul;68(1):139-46. (PMID: 25151013)
BJU Int. 2019 May;123(5):854-860. (PMID: 30288918)
Nat Rev Urol. 2015 Mar;12(3):130-1. (PMID: 25644161)
Eur Urol Focus. 2018 Apr;4(3):385-387. (PMID: 28753831)
Eur Urol. 2015 Sep;68(3):438-50. (PMID: 25480312)
Clin Cancer Res. 2007 Sep 1;13(17):5103-8. (PMID: 17785564)
Eur Urol. 2015 Nov;68(5):e106-7. (PMID: 26215600)
JMIR Cancer. 2017 Jan 06;3(1):e1. (PMID: 28410180)
J Urol. 2008 Oct;180(4):1303-8; discussion 1308. (PMID: 18707724)
Rev Urol. 2017;19(1):1-10. (PMID: 28522924)
Cancer. 2018 Jan 15;124(2):278-285. (PMID: 28976544)
Eur Urol. 2017 Apr;71(4):618-629. (PMID: 27568654)
JAMA. 2015 Jan 27;313(4):390-7. (PMID: 25626035)
Eur Urol. 2006 May;49(5):820-6. (PMID: 16439050)
J Urol. 2005 Jun;173(6):1930-4. (PMID: 15879784)
J Clin Oncol. 2007 Aug 20;25(24):3582-8. (PMID: 17704405)
Urology. 2006 Apr;67(4):762-8. (PMID: 16600352)
World J Urol. 2018 Apr;36(4):565-573. (PMID: 29222595)
Prostate. 2017 Oct;77(14):1401-1407. (PMID: 28853167)
Eur Urol Oncol. 2018 Jun;1(2):109-117. (PMID: 31100233)
Eur Urol. 2016 Jun;69(6):1129-34. (PMID: 26651990)
World J Urol. 2019 Feb;37(2):243-251. (PMID: 29967944)
Transl Androl Urol. 2018 Feb;7(1):18-26. (PMID: 29594016)
Rev Urol. 2015;17(1):3-13. (PMID: 26028995)
Cancer. 2018 Mar 15;124(6):1197-1206. (PMID: 29211316)
فهرسة مساهمة: Keywords: biomarker; cost-effective diagnostic pathways; magnetic resonance imaging; prostate cancer detection; risk calculator; risk stratification
المشرفين على المادة: 0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20190417 Date Completed: 20190730 Latest Revision: 20231011
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC6480079
DOI: 10.3390/ijms20071637
PMID: 30986955
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms20071637